Li, Haoxin
Ma, Tiantai
Remsberg, Jarrett R. http://orcid.org/0000-0002-5234-0168
Won, Sang Joon http://orcid.org/0000-0002-8148-7652
DeMeester, Kristen E.
Njomen, Evert
Ogasawara, Daisuke http://orcid.org/0000-0002-2178-4698
Zhao, Kevin T. http://orcid.org/0000-0003-3440-2094
Huang, Tony P.
Lu, Bingwen
Simon, Gabriel M.
Melillo, Bruno http://orcid.org/0000-0002-9708-5287
Schreiber, Stuart L. http://orcid.org/0000-0003-1922-7558
Lykke-Andersen, Jens
Liu, David R. http://orcid.org/0000-0002-9943-7557
Cravatt, Benjamin F. http://orcid.org/0000-0001-5330-3492
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA231991)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118069, GM118062)
Article History
Received: 1 February 2023
Accepted: 24 August 2023
First Online: 2 October 2023
Competing interests
: B.F.C. is a founder and scientific advisor to Vividion Therapeutics. D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver genome editing or epigenome engineering agents. The other authors declare no competing interests.